✦ LIBER ✦

A phase III trial of taxotere and doxorubicin (AT) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: an interim analysis

✍ Scribed by K. Bouzid; J. Vinholes; F. Salas; E. Mickiewicz; S. Valdivia; V. Ostapenko; E. Baltali; N. Ghilezan; A.L. Courtin; N. Badri

Book ID: 117658465
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 182 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)81100-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized open-label phase III multicen

Randomized open-label phase III multicenter trial comparing TAXOL®/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer

✍ Płuż;zańska, A.; Jassem, J.; Jelič, S.; Gorbunova, V.; Mrsič-Krmpotič, Z.; Berzi 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 152 KB

A prospective, randomized phase III tria

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma

✍ Cesar Blajman; L. Balbiani; J. Block; F. Coppola; R. Chacon; L. Fein; S. Bonicat 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

## Background: A prospective, multicenter, randomized, phase iii trial comparing the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (fac) with a combination of vinorelbine and doxorubicin (na) in the treatment of patients with advanced breast carcinoma w

Prospective randomized trial of 5-fluoro

Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control

✍ Jeffrey M. Albert; Aman U. Buzdar; Reina Guzman; Pamela K. Allen; Eric A. Strom; 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 240 KB

Sixteen years follow-up results of a ran

Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience

✍ Leone, JosÃ© Pablo; Leone, Julieta; Vallejo, Carlos Teodoro; PÃ©rez, Juan Eduard 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 359 KB

PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WI

PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN FRANCE

✍ H Miadi-Fargier; C Le Pen; MC Woronoff-Lemsi; JP Guastalla; X Pivot; H Roché; F 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

A phase III randomized trial of cyclopho

A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer

✍ M. C. Alonso; J. M. Tabernero; B. Ojeda; M. Llanos; C. Solà; M. A. Climent; M. A 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 788 KB